Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosis.

Abstract

Background: People with relapsing forms of multiple sclerosis (PwRMS) treated with ofatumumab, a fully human anti-CD20 monoclonal antibody, can experience local/systemic injection-related reactions (IRRs). However, data on the occurrence and management of local/systemic IRRs in real-world clinical settings are limited.

Objective: This study aimed to better understand clinicians' perspectives regarding occurrence and management of local/systemic IRRs among PwRMS treated with ofatumumab in clinical practice.

Methods: A panel of US-based neurologists and advanced practice providers experienced with ofatumumab therapy in PwRMS participated in a three-round online modified Delphi study. In round 1, participants completed a demographics survey and Delphi questionnaire on IRR management. In round 2, they attended a live webinar to obtain feedback on round 1 results. In round 3, they reviewed round 1 and 2 feedback and provided their final responses.

Results: Forty participants (neurologists, n = 31; nurse practitioners, n = 5; and physician assistants, n = 4) completed all three rounds. Participants strongly agreed that local/systemic IRRs, regardless of severity, were unlikely with ofatumumab. Pre-/post-treatment of systemic IRRs was not uniformly required.

Conclusion: This study gives health care providers insight into the potential occurrence and management of IRRs with ofatumumab in the clinical practice setting.